Core Insights - The company reported a revenue of 8.744 billion yuan for 2024, representing a year-on-year growth of 15.85% [2] - The net profit attributable to shareholders reached 662 million yuan, an increase of 26.89% compared to the previous year [2] - The net profit excluding non-recurring gains and losses was 538 million yuan, up by 22.31% year-on-year [2] R&D and Innovation - The company invested approximately 708 million yuan in R&D, accounting for 8.10% of its total revenue for 2024 [2] - As of the end of 2024, the company had applied for a total of 4,782 patents, with 814 new applications in 2024 [2] - The new patents included 267 for 5G antennas, 11 for LCP, 23 for UWB, 32 for WPC, 18 for BTB connectors, 41 for MLCC, and 271 for acoustic structures [2] Product Development - The company is actively developing products such as flexible reconfigurable antennas, satellite communication phased array antennas, and millimeter-wave radar gap waveguide antennas [3] - In the wireless charging sector, the company has developed technologies for NFC wireless charging and Qi2.0/Ki [3] - The company has achieved full-chain coverage from materials to modules for low-loss, high-precision antenna solutions, entering the North American customer supply chain [3] Market Position and Demand - The company is focusing on high-end passive components, with high-end MLCC products passing major customer tests and gradually entering mass production [3] - There is a noticeable demand growth for high-end MLCC products driven by emerging fields such as AI servers, leading to a strategic layout for high-end MLCC product series [3]

Group 1: 康方生物 (Kangfang Biologics) - The approval for the listing application of Ivosidenib for 1L PD-L1 positive NSCLC in mainland China was granted earlier than expected, with the first interim overall survival (OS) data showing a hazard ratio (HR) of 0.777, indicating a 22.3% reduction in the risk of death [1][2] - The market should focus on the subsequent and final OS analysis results, as the current interim analysis has a low alpha value and a small sample size [1] - The successful approval reflects the regulatory body's recognition of the trend in OS benefits, suggesting limited impact on the clinical and commercial value of Ivosidenib in the mainland market from future OS HR results [1] Group 2: 卓胜微 (Zhuosheng Micro) - In Q1 2025, the revenue decreased by 36.5% year-on-year to 756 million RMB, primarily due to weaker seasonal changes in 2024 [3] - The company reported a net loss of 47 million RMB, transitioning from profit to loss, with a non-recurring net profit loss of 54 million RMB and a gross margin of 31.0%, down 540 basis points quarter-on-quarter [3] - Management anticipates a significant revenue increase in the second half of 2025, driven by seasonal demand for RF products and the launch of new products like PAMiD [3][4] Group 3: 中国太保 (China Pacific Insurance) - In Q1, the net profit attributable to shareholders decreased by 18.1% year-on-year, mainly due to a 15% decline in investment income [8] - The new business value grew by 11.3% year-on-year, with a comparable growth of 39.0%, indicating strong performance in the insurance sector [8] - The comprehensive cost ratio for property and casualty insurance improved, with a combined ratio of 97.4%, down 0.6 percentage points year-on-year [8] Group 4: 中国平安保险 (Ping An Insurance) - The operating profit attributable to shareholders grew by 2.4% year-on-year, primarily driven by the life and health insurance sectors [9] - The net profit attributable to shareholders decreased by 26.4% year-on-year, significantly lower than the operating profit growth [9] - The new business value growth exceeded expectations, with a significant improvement in the value rate, and the comprehensive cost ratio for property and casualty insurance showed notable improvement [9] Group 5: 新奧能源 (Xinao Energy) - In Q1, the retail gas volume increased by 0.3% year-on-year, outperforming the 2.2% decline in apparent natural gas consumption in mainland China [10] - The company experienced a 16% year-on-year decrease in new residential connections, which was within expectations [10] - The privatization plan is progressing steadily, with expectations for shareholder approval in Q4 of this year [10]

4月28日，通宇通讯接受蜂巢基金、生命保险资产管理、中信建投证券等超80家机构线上调研，机构类 型为公募、券商、私募、银行理财子、保险、信托公司等机构。期间管理层就公司战略规划、技术研 发、市场拓展等议题展开深度交流。此次调研进一步凸显了资本市场对通宇通讯在通信领域核心竞争力 的高度关注，而其2024年报及2025年一季报披露的业绩增长与创新成果，则为机构投资者注入了一 剂"强心针"。 据了解，作为国内通信天线及射频器件行业的领军企业，通宇通讯在通信领域已深耕多年，专注于通信 天线、射频器件、微波天线等产品的研发、生产与销售，服务全球多家知名通信运营商和设备集成商。 年报显示，公司实现营业收入 11.94 亿元，销售毛利率较上年同期增长 6.73 个百分点至 22.21%。这一 成绩的取得，不仅体现了公司在复杂市场环境中的良好发展态势，更反映出其主营业务盈利能力的持续 改善。公司通过优化内部管理、提升运营效率等一系列举措，有效降低了成本，提高了产品的附加值， 从而推动了毛利率的提升。 在投资者互动环节中，通宇通讯对2024年及2025年一季度的营收构成及整体经营情况、市场格局及竞争 态势、卫星通信市场的布局以 ...

近年，全球通信产业链面临复杂多元的考验。5G市场出现周期波动、高集成模组技术迭代导 致壁垒高企，叠加全球贸易环境极大不确定性引发的供应链重塑压力，行业调整进入深水 期。目前中国通信产业面临外部断链、行业周期、同质竞争、技术迭代等艰难局面。在不确 定性成为常态的产业环境中，只有坚持底层技术突破，才能实现中国半导体产业的技术平 权，为国内外客户提供多样化选择。 在此背景下，慧智微（688512.SH）于4月28日发布2025年第一季度业绩报告，报告显示公司营业 收入与净利润同比增长，实现盈利。近年，慧智微立足自主架构，面向行业领先技术，服务头部客 户 ， 从 5G L-PAMiF 模 组 的 率 先 量 产 ， 到 Phase8L L-PAMiD 高 集 成 模 组 与 国 际 厂 商 同 时 同 质 量 产，其创新路径始终围绕"自主可控"与"场景落地"双轴展开。通过Phase8L L-PAMiD国产化突 破、小尺寸双频 L-PAMiF的产品引领，慧智微5G高集成模组核心能力不断积累和体现，逐步在高 端、旗舰产品序列构筑差异化竞争力，在不确定的环境下为国内外客户提供确定性的选择。 Phase8L L-PAMiD国 ...

Core Viewpoint - Tongyu Communication has demonstrated resilience and growth in the telecommunications industry, achieving significant revenue and profit increases despite market challenges [1][2]. Financial Performance - The company reported an annual revenue of 1.194 billion yuan, with a gross profit margin increase of 6.73 percentage points to 22.21% [1][2]. - In Q1 2025, Tongyu Communication achieved a revenue of 251 million yuan, a year-on-year growth of 6.08%, and a net profit of 11.182 million yuan, up 128.26% year-on-year [1][2]. Overseas Business Development - The overseas revenue reached 436 million yuan in 2024, marking a 21.29% increase and accounting for 36.51% of total revenue [2]. - The gross profit margin for overseas revenue was 25.52%, significantly higher than that of domestic revenue, attributed to successful expansion in markets such as Belt and Road countries and Southeast Asia [2]. Satellite Communication Strategy - Tongyu Communication has strategically invested in satellite communication since acquiring Xi'an Xinghengtong in 2017, establishing a comprehensive product system [3][4]. - The company has launched several initiatives, including the establishment of Chengdu Juji Millimeter Wave Technology Co., Ltd. and partnerships to enhance its capabilities in satellite communication [3][4]. R&D and Future Technologies - The company invested 96.036 million yuan in R&D, representing 8.04% of its revenue, highlighting its commitment to technological innovation [2]. - Tongyu Communication is actively involved in the development of 6G technology, with plans to start standard research in June 2025 [5][6]. Market Position and Competitive Advantage - The company has established strong partnerships with major domestic and international telecom operators, with its products used in over 70 countries [6]. - Tongyu Communication's early entry into 5G technology with the AFU product has solidified its leading position and provided a foundation for future advancements in 6G [6][7].

更多资料加入知识星球：水木调研纪要 关注公众号：水木纪要 卓胜微 - A 短期阵痛，长期获益；评级下调至"减持" ▼ 我们认为长期来看卓胜微可巩固其市场和技术龙头地位，这得益于其垂 直整合策略（从而最终提供有吸引力的成本结构和先进的模块产品）。 不过，短期盈利压力可能延续到未来几个季度，原因是公司自有产能爬 坡造成费用上升和价格竞争（低端分立产品以价换量/市场份额策略）。 同时，安卓智能手机需求弱于预期，以及和村田的潜在知识产权纠纷都 是短期估值的不利因素。我们将卓胜微的评级下调至"减持"，并基于 22 倍的动态市盈率得出截至 2026 年 6 月的目标价 56.0 元，同时我们建 议在 2025 年下半年予以重新审视，原因是盈利可能好转和手机旗舰机型 的先进射频模块份额上升。 中国 证券研究 2025 年 4 月 10 日 ▼ 减持 300782.SZ, 300782 CH 股价（2025 年 4 月 9 日）： 74.45 元 目标价（2026 年 6 月）： 56.00 元 之前（2024 年 12 月）： 162.00 元 证券研究报告 科技 证券分析师: 冯令天 AC (86-21) 6106 63 ...

以下文章来源于数据宝 ，作者张智博 数据宝 . 从解禁规模上看，10股解禁市值超过5亿元。卓兆点胶、唯捷创芯解禁市值居前，分别为17.99亿元、17.53亿元。10股中，万里石、洪城环境和新华制药解 禁股类型为定向增发机构配售股份解禁，其余7股均为首发原股东限售股份解禁。 数据宝——证券时报智能原创新媒体，中国股市大数据新媒体领先品牌，依托证券时报财经数据库和证监会指定信息披露媒体的权威信息，让您用手机也 能从海量数据中获得有用的决策信息支持，数据是个宝，炒股少烦恼！ 下周31股解禁，对应解禁市值逾110亿元。 矿产龙头发布炸裂一季报 昨日晚间，矿业龙头紫金矿业发布2025年第一季度报告。 公司一季度实现营业收入789.28亿元，同比增长5.55%；归母净利润101.67亿元，同比增长62.39%。业绩增长主要是公司生产运营管理能力稳步提升，主要 矿产品产量实现增长；同时公司对金属市场的研判能力进一步提升，充分享受了金属价格上涨带来的收益。 从生产经营数据来看，2025年1—3月，公司矿产金产量同比增加13%，矿产铜产量同比增加9%，矿产锌产量同比下降10%。矿山企业毛利率为59.94%，同 比增长5.44个 ...